A case report of a patient with rheumatoid arthritis complicated with Mycobacterium avium during tocilizumab treatment

Modern Rheumatology

Volumn 21, Issue 6, 2011, Pages 655-659

  Nakahara, Hideko ^a   Kamide, Yosuke ^b   Hamano, Yoshimasa ^a   Hosokawa, Takashi ^a   Nishide, Masayuki ^a   Lin, Yu ^a   Kawamoto, Keisuke ^a   Fusama, Mie ^a   Higa, Shinji ^a   Kuroiwa, Takashi ^c   Igarashi, Tsuyoshi ^a   Kuritani, Taro ^a   Maeda, Keiji ^a  

^a OSAKA POLICE HOSPITAL   (Japan)

^b GUNMA UNIVERSITY   (Japan)

^c GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti IL 6 receptor antibody; Biologics; IL 6; MAC; TNF

Indexed keywords

CLARITHROMYCIN; ETHAMBUTOL; GOLD SALT; METHOTREXATE; PREDNISOLONE; RIFAMPICIN; SALAZOSULFAPYRIDINE; TOCILIZUMAB;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; ATYPICAL MYCOBACTERIOSIS; CASE REPORT; COMBINATION CHEMOTHERAPY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; MYCOBACTERIUM AVIUM; PRIORITY JOURNAL; REMISSION; RETREATMENT; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ANTITUBERCULAR AGENTS; ARTHRITIS, RHEUMATOID; CLARITHROMYCIN; ETHAMBUTOL; FEMALE; HUMANS; MIDDLE AGED; MYCOBACTERIUM AVIUM; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; RIFAMPIN; TREATMENT OUTCOME;

EID: 84855696016     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0448-1     Document Type: Article

References (33)

1. Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med. 1990;322:1277-89. (Pubitemid 20152491)
2. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy usedfor rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162-7. (Pubitemid 47309731)
3. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): Significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19:12-9.
4. Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: Meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol. 2010;20:222-32.
5. Benson CA, Ellner JJ. Mycobacterium avium complex infection and AIDS: Advances in theory and practice. Clin Infect Dis. 1993;17:7-20. (Pubitemid 23197558)
6. Okubo H, Iwamoto M, Yoshio T, Okazaki H, Bandoh M, Minota S. Rapidly aggravated Mycobacterium avium infection in a patient with rheumatoid arthritis treated with infliximab. Mod Rheum. 2005;15:62-4. (Pubitemid 40298426)
7. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24. (Pubitemid 18091653)
8. Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H, Sato B, et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol. 2003;30:1426-35. (Pubitemid 36835435)
9. Horsburgh CR. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med. 1991; 324:1332-8.
10. Opravil M. Epidemiological and clinical aspects of mycobacterial infections. Infection. 1997;25:56-9.
11. Medical Section of the American Lung Association. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med. 1997;156(2 pt 2):S1-25.
12. Hsu N, Young LS, Bermudez LE. Response to stimulation with recombinant cytokines and synthesis of cytokines by murine intestinal macrophages infected with the Mycobacterium avium complex. Infect Immun. 1995;63:528-33.
13. Jacobs M, Togbe D, Fremond C, Samarina A, Allie N, Botha T, et al. Tumor necrosis factor is critical to control tuberculosis infection. Microbes Infect. 2007;9:623-8. (Pubitemid 46628779)
14. Appelberg R, Castro AG, Pedrosa J, Silva RA, Orme IM, et al. Role of gamma interferon and tumor necrosis factor alpha during T-cell-independent and -dependent phases of Mycobacterium avium infection. Infect Immun. 1994;62:3962-71. (Pubitemid 24264343)
15. Gomez-Flores R, Tucker SD, Kansal R, Tamez-Guerra R, Mehta RT. Enhancement of antibacterial activity of clofazimine against Mycobacterium avium-Mycobacterium intracellulare complex infection induced by IFN-c is mediated by TNF-α. J Antimicrob Chemother. 1997;39:189-97. (Pubitemid 27116413)
16. Bekker LG, Freeman S, Murray PJ, Ryffel B, Kaplan G. TNF-α controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase- independent pathways. J Immunol. 2001;166:6728-34. (Pubitemid 32467216)
17. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-104.
18. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum. 2003;48:2122-7. (Pubitemid 36959191)
19. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: Differential modes of action of infliximab and etanercept? Clin Infect Dis. 2005;41(Suppl 3):S199-203. (Pubitemid 41022091)
20. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69:522-8.
21. Mohan VP, Scanga CA, Yu K, Scott HM, Tanaka KE, Tsang E, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: Possible role for limiting pathology. Infect Immun. 2001;69:1847-55. (Pubitemid 32187645)
22. Ogata A, Mori M, Hashimoto S, Yano Y, Fujikawa T, Kawai M, et al. Minimal influence of tocilizumab on IFN-c synthesis by tuberculosis antigens. Mod Rheumatol. 2010;20:130-3.
23. Tomioka H, Maw WW, Sato K, Sato H. The role of tumour necrosis factor-a in combination with interferon-c or interleukin- 1 in the induction of immunosuppressive macrophages because of Mycobacterium avium complex infection. Immunology. 1996;88: 61-7. (Pubitemid 26166377)
24. Yamada T, Nakajima A, Inoue E, Tanaka E, Hara M, Tomatsu T, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis. 2006;65:1661-3. (Pubitemid 44799684)
25. Klebanoff SJ, Vadas MA, Harlan JM, Sparks LH, Gamble JR, Agosti JM, et al. Stimulation of neutrophils by tumor necrosis factor. J Immunol. 1986;136:4220-5. (Pubitemid 16123075)
26. Neumann B, Machleidt T, Lifka A, Pfeffer K, Vestweber D, Mak TW, et al. Crucial role of 55-kilodalton TNF receptor in TNFinduced adhesion molecule expression and leukocyte organ infiltration. J Immunol. 1996;156:1587-93. (Pubitemid 26065871)
27. Nakamatsu M, Yamamoto N, Hatta M, Nakasone C, Kinjo T, Miyagi K, et al. Role of interferon-gamma in Valpha14? natural killer T cell-mediated host defense against Streptococcus pneumoniae infection in murine lungs. Microbes Infect. 2007;9:364-74.
28. Ruan S, Young E, Luce MJ, Reiser J, Kolls JK, Shellito JE. Conditional expression of interferon-gamma to enhance host responses to pulmonary bacterial infection. Pulm Pharmacol Ther. 2006;19:251-7.
29. Sutherland RE, Olsen JS, McKinstry A, Villalta SA, Wolters PJ. Mast cell IL-6 improves survival from Klebsiella pneumonia and sepsis by enhancing neutrophil killing. J Immunol. 2008;181:5598-605.
30. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189-94. (Pubitemid 351183307)
31. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Post-marketing surveillance program of tocilizumab for RA in Japan-interim analyses of 3,881 patients. Arthritis Rheum. 2010;62(10):S168.
32. Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol. 2009;36:898-906.
33. Nishimoto N, Japanese MRA Study Group for RA. Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis at recurrence (RESTORE study). Ann Rheum Dis. 2010;69(Suppl 3):537.